Score Overview
Explore the 2021 public Archive ranking →
Where Supernus Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- SUPN
2017: 2.2% · 2021: 18.2% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 43.97 | — |
1 Year2025-09-29 | $ 47.60 | -7.63% |
5 Years2021-09-29 | $ 26.85 | 63.76% |
10 Years2016-09-29 | $ 24.63 | 78.52% |
All Time2012-05-01 | $ 5.37 | 8x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | All Time2012-05-01 |
|---|---|---|---|---|---|
| Price | $ 43.97 | $ 47.60 | $ 26.85 | $ 24.63 | $ 5.37 |
| Return | — | -7.63% | 63.76% | 78.52% | 8x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 830M | -$ 109M | $ 372M |
| 2025 | $ 718M | -$ 38M | $ 308M |
| 2024 | $ 661M | $ 73M | $ 453M |
| 2023 | $ 607M | $ 1M | $ 254M |
| 2022 | $ 667M | $ 60M | $ 461M |
| 2021 | $ 579M | $ 53M | $ 339M |
| 2020 | $ 520M | $ 126M | $ 422M |
| 2019 | $ 392M | $ 113M | $ 347M |
| 2018 | $ 408M | $ 110M | $ 356M |
| 2017 | $ 302M | $ 57M | $ 140M |
| 2016 | $ 215M | $ 91M | $ 90M |
| 2015 | $ 144M | $ 14M | $ 62M |
| 2014 | $ 122M | $ 19M | $ 74M |
| 2013 | $ 12M | -$ 92M | $ 82M |
| IPO2012 | $ 1M | -$ 46M | $ 88M |
Supernus Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 520M to $ 718M and net income went from $ 126M to -$ 38M. Revenue increased in 4 of those 5 years; net income in 2.
Between 2015 and 2025, revenue grew from $ 144M to $ 718M and net income went from $ 14M to -$ 38M. Revenue increased in 8 of those 10 years; net income in 5.
Supernus Pharmaceuticals Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Membership
Continue SUPN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
NanobiotixNBTX· revenue grew in 60% of years
Rani Therapeutics Holdings IncRANI· revenue grew in 60% of years
4D Molecular Therapeutics IncFDMT· revenue grew in 67% of years
Intellia Therapeutics IncNTLA· revenue grew in 60% of years
Pacific Biosciences of CaliforniaPACB· revenue grew in 40% of years
